

Current report 23/2020

15 LIPCA 2020 r.

Determination of the issue price of Series I shares issued by Ryvu Therapeutics S.A., the number of Series I shares to be offered for subscription by Ryvu Therapeutics S.A. and execution of the pricing supplement to the placement agreement

THIS CURRENT REPORT AND THE INFORMATION HEREIN, IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE, TRANSMISSION, DISTRIBUTION, OR FORWARDING DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL. THIS CURRENT REPORT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.

PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS CURRENT REPORT.

With reference to the current reports no. 20/2020 (dated 13 July 2020) and no. 22/2020 (dated 13 July 2020), the Management Board of Ryvu Therapeutics S.A. with its registered office in Kraków (the "**Company**") announces that acting pursuant to the authorization granted under Resolution No. 4 of the Extraordinary General Meeting of the Company of 13 July 2020 on increasing share capital through an issue of ordinary series I bearer shares (the "**Series I Shares**"), with a complete exclusion of the pre-emptive rights of existing shareholders, on dematerialization of series I shares and rights to these shares, application for admission and introduction to trading on the regulated market of series I shares and the rights to these shares and on amending the Company's Articles of Association ("**Issue Resolution**"), the Management Board of the Company, upon the completion of the accelerated book-building for Series I Shares on 15 July 2020, has determined as follows:

- (1) the issue price of the Series I Shares will be equal to PLN 60.00 per Series I Share;
- (2) the Company will place offers to investors to subscribe for 2,384,245 Series I Shares in total.

The Management Board of the Company also informs that on 15 July 2020, the Company entered into the Pricing Supplement to the Placement Agreement of 13 July 2020, executed by the Company, UBS Europe SE and IPOPEMA Securities S.A. (the "**Pricing Supplement**"). Under the Pricing Supplement, the parties thereto determined the issue price of the Series I Shares and the final number of Series I Shares offered for subscription, as provided in this current report, as well as an initial allocation list of the Series I Shares to investors to whom the Company will submit the offers to subscribe for the Series I Shares in accordance with the Issue Resolution.

IMPORTANT NOTICES

This current report was prepared in accordance with (i) Article 17 Section 1 of the Regulation No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and (ii) Article 56 Section 1 Item 2 of the Act of 29 July 2005 on Public Offerings, the Conditions for Introducing Financial Instruments to an Organised Trading System, and Public Companies.

This current report is solely for information purposes and is published by Ryvu Therapeutics S.A. (the "**Company**") exclusively in order to provide essential information on the terms of issuance and offering of its new shares. This current report is by no means intended, whether directly or indirectly, to promote the offering, subscription or purchase of the shares of the Company referred to in this current report (the "**Placing Shares**") and does not represent advertisement or promotional material prepared or published by the Company for the purpose of promoting the Placing Shares or their offering or subscription or for the purpose of encouraging an investor, whether directly or indirectly, to subscribe for or acquire the Placing Shares. The Company has not published and has no intention of publishing any materials aimed at promoting the Placing Shares or their offering or subscription after the date of this current report.

This current report and the information contained in it is not for publication, release, transmission, distribution or forwarding, in whole or in part, directly or indirectly, in or into the United States, Australia, Canada, Japan or South Africa or any other jurisdiction in which publication, release or distribution would be unlawful. This current report does not constitute an offer to sell or issue, or the solicitation of an offer to buy, acquire or subscribe for shares in the capital of the Company in the United States, Australia, Canada, Japan or South Africa or any other state or jurisdiction. This current report has not been approved by any supervising authority or stock exchange. Any failure to comply with these restrictions may constitute a violation of the securities laws of such jurisdictions.

The Placing Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "**Securities Act**") or with any securities regulatory authority of any state or other jurisdiction of the United States and may not be offered, sold, pledged, taken up, resold, transferred or delivered, directly or indirectly, in or into the United States absent

registration under the Securities Act, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. The Placing Shares have not been approved, disapproved or recommended by the U.S. Securities and Exchange Commission, any state securities commission in the United States or any other U.S. regulatory authority, nor have any of the foregoing authorities passed upon or endorsed the merits of the offering of the Placing Shares. Subject to certain exceptions, the securities referred to herein may not be offered or sold in the United States, Australia, Canada, Japan, South Africa or to, or for the account or benefit of, any national, resident or citizen of the United States, Australia, Canada, Japan, the Republic of South Africa.

No public offering of the Placing Shares is being made in the United States, United Kingdom or elsewhere outside Poland. All offers of the Placing Shares will be made pursuant to an exemption under the Prospectus Regulation (EU) 2017/1129, as amended from time to time (including any relevant implementing measure in any member state, the "**Prospectus Regulation**"), from the requirement to publish a prospectus. This current report is being distributed to persons in the United Kingdom only in circumstances in which section 21(1) of the Financial Services and Markets Act 2000, as amended ("**FSMA**") does not apply.

No prospectus will be made available in connection with the matters contained in this current report and no such prospectus is required (in accordance with the Prospectus Regulation) to be published. This current report and the terms and conditions set out herein are directed only at persons who are: (a) persons in Member States of the European Economic Area who are qualified investors (within the meaning of article 2(e) of the Prospectus Regulation ("**Qualified Investors**")); and (b) in the United Kingdom, Qualified Investors who are persons who (i) have professional experience in matters relating to investments falling within the definition of "investment professionals" in article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "**Order**"); (ii) are persons falling within article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Order; or (iii) are persons to whom it may otherwise be lawfully communicated; (all such persons together being referred to as "relevant persons"). This current report and the terms and conditions set out herein must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this current report and the terms and conditions set out herein relates is available only to relevant persons and will be engaged in only with relevant persons.

This current report has been issued by, and is the sole responsibility of, the Company. No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by UBS Europe SE or IPOPEMA Securities S.A. as the managers of the offering of the Placing Shares (the "**Managers**"), or by any of their or their respective affiliates or agents as to or in relation to, the contents of the information contained in this current report, the accuracy, completeness or sufficiency of this current report or any other written or oral information made available to or publicly available to any interested

party or its advisers, and any liability therefore is expressly disclaimed. Each of the Managers is acting solely for the Company and no one else in connection with the offering of the Placing Shares and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients nor for providing advice in relation to the offering of the Placing Shares and/or any other matter referred to in this current report.

The distribution of this current report and/or the information about the offering and subscription for the Placing Shares in certain jurisdictions may be restricted by law. No action has been taken by the Company, the Managers or any of their respective affiliates that would, or which is intended to, permit an offering of the Placing Shares in any jurisdiction or result in the possession or distribution of this current report or any other offering or publicity material relating to the Placing Shares in any jurisdiction where action for that purpose is required.

Persons distributing any part of this current report must satisfy themselves that it is lawful to do so.

This current report does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Placing Shares. Any investment decision to subscribe for the Placing Shares in the offering must be made solely on the basis of publicly available information, which has not been independently verified by the Managers.

This current report does not constitute an invitation to underwrite, subscribe for or otherwise acquire or dispose of any securities in any jurisdiction. This current report does not constitute a recommendation concerning any investor's option with respect to the offering, subscription and/or purchase of the Placing Shares. Each investor or prospective investor should conduct his, her or its own investigation, analysis and evaluation of the business and data described in this current report and publicly available information. The price and value of securities can go down as well as up. Past performance is not a guide to future performance.

Legal basis: art. 17.1 Market Abuse Regulation

Representatives of the Company:

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka – Vice President of the Management Board